1921
Volume 94, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract

The first oral cholera vaccine (OCV) campaign, since its prequalification by the World Health Organization, in response to an ongoing cholera epidemic (reactive vaccination) was successfully conducted in a poor urban slum of approximately 70,000 inhabitants in Port-au-Prince, Haiti, in 2012. Vaccine coverage was 75% of the target population. This report documents the impact of OCV in reducing the number of culture-confirmed cases of cholera admitted to the Groupe Haïtien d'Etude du Sarcome de Kaposi et des Infections Opportunistes (GHESKIO) cholera treatment center from that community in the 37 months postvaccination (April 2012–April 30, 2015). Of 1,788 patients with culture-confirmed cholera, 1,770 (99%) were either from outside the vaccine area (1,400 cases) or from the vaccinated community who had not received OCV (370 cases). Of the 388 people from the catchment area who developed culture-confirmed cholera, 370 occurred among the 17,643 people who had not been vaccinated (2.1%) and the remaining 18 occurred among the 52,357 people (0.034%) who had been vaccinated ( < 0.001), for an efficacy that approximates 97.5%. Despite not being designed as a randomized control trial, the very high efficacy is a strong evidence for the effectiveness of OCV as part of an integrated package for the control of cholera in outbreak settings.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.15-0700
2016-05-04
2017-11-24
Loading full text...

Full text loading...

/deliver/fulltext/14761645/94/5/1136.html?itemId=/content/journals/10.4269/ajtmh.15-0700&mimeType=html&fmt=ahah

References

  1. Centers for Disease Control and Prevention, 2010. Cholera outbreak—Haiti, October 2010. MMWR Morb Mortal Wkly Rep 59: 1411.
  2. Centers for Disease Control and Prevention, 2010. Update: outbreak of Cholera—Haiti. MMWR Morb Mortal Wkly. Rep 59: 15861590.
  3. World Health Organization, 2011. Cholera Annual Report, 2010. Wkly Epidemiol Rec 31: 325340.
  4. Date KA, Vicari A, Hyde TB, Mintz E, Danovaro-Holliday MC, Henry A, Tappero JW, Roels TH, Abrams J, Burkholder BT, Ruiz-Matus C, Andrus J, Dietz V, , 2011. Considerations for oral cholera vaccine use during outbreak after earthquake in Haiti, 2010–2011. Emerg Infect Dis 17: 21052112.[Crossref]
  5. World Health Organization, 2012. Cholera Annual Report, 2011. Wkly Epidemiol Rec 87: 289304.
  6. Valcin CL, Severe K, Riche CT, Anglade BS, Moise CG, Woodworth M, Charles M, Li Z, Joseph P, Pape JW, Wright PF, , 2013. Predictors of disease severity in patients admitted to a cholera treatment center in urban haiti. Am J Trop Med Hyg 89: 625632.[Crossref]
  7. Charles M, Delva GG, Boutin J, Severe K, Peck M, Mabou MM, Wright PF, Pape JW, , 2014. Importace of cholera and other etiologies of acute diarrhea in post-earthquake Port-au-Prince, Haiti. Am J Trop Med Hyg 90: 511517.[Crossref]
  8. Ali M, Nelson AR, Lopez AL, Sack DA, , 2015. Updated global burden of cholera in endemic countries. PLoS Negl Trop Dis 9: e0003832.[Crossref]
  9. UNICEF Statistics at a glance: Haiti. Available at: http://www.unicef.org/infobycountry/haiti_statistics.html. Accessed September 30, 2014.
  10. Ivers LC, Farmer P, Almazor CP, Léandre F, , 2010. Five complementary interventions to slow cholera: Haiti. Lancet 376: 20482051.[Crossref]
  11. Reyburn R, Deen JL, Grais RF, Bhattacharya SK, Sur D, Lopez AL, Jiddawi MS, Clemens JD, von Seidlein L, , 2011. The case for reactive mass oral cholera vaccinations. PLoS Negl Trop Dis 5: e952.[Crossref]
  12. Von Seidlein L, Deen JL, , 2012. Considerations for oral cholera vaccine use during outbreak after earthquake in Haiti, 2010–2011. Emerg Infect Dis 18: 12111214.[Crossref]
  13. Chao DL, Halloran ME, Longini IM, Jr, 2011. Vaccination strategies for epidemic cholera in Haiti with implications for the developing world. Proc Natl Acad Sci USA 108: 70817085.[Crossref]
  14. Ivers LC, Farmer P, Pape JW, , 2012. Oral cholera vaccine and integrated cholera control in Haiti. Lancet 379: 20262028.[Crossref]
  15. Ivers LC, Teng JE, Lascher J, Raymond M, Weigel J, Victor N, Jerome JG, Hilaire IJ, Almazor CP, Ternier R, Cadet J, Francois J, Guillaume FD, Farmer PE, , 2013. Use of oral cholera vaccine in Haiti: a rural demonstration project. Am J Trop Med Hyg 89: 617624.[Crossref]
  16. Rouzier V, Severe K, Juste MA, Peck M, Perodin C, Severe P, Deschamps MM, Verdier RI, Prince S, Francois J, Cadet JR, Guillaume FD, Wright PF, Pape JW, , 2013. Cholera vaccination in urban Haiti. Am J Trop Med Hyg 89: 671681.[Crossref]
  17. Martin S, Costa A, Perea W, , 2012. Stockpiling oral cholera vaccine. Bull World Health Organ 90: 714.[Crossref]
  18. Martin S, Lopez AL, Bellos A, Deen J, Ali M, Alberti K, Anh DD, Costa A, Grais RF, Legros D, Luquero FJ, Ghai MB, Perea W, Sack DA, , 2014. Post-licensure deployment of oral cholera vaccines: a systematic review. Bull World Health Organ 92: 881893.[Crossref]
  19. Pape JW, Deschamps MM, Ford H, Joseph P, Johnson WD, Jr Fitzgerald DW, , 2010. The GHESKIO refugee camp after the earthquake in Haiti–dispatch 2 from Port-au-Prince. N Engl J Med 362: e27.[Crossref]
  20. Orenstein WA, Bernier RH, Dondero TJ, Hinman AR, Marks JS, Bart KJ, Sirotkin B, , 1985. Field evaluation of vaccine efficacy. Bull World Health Organ 63: 10551068.
  21. Schnirring L, Roos R, , 2014. Cholera vaccine worked well during outbreak. Center for Infectious Disease Research and Policy. CIDRAP News, May 29, 2014.
  22. Luquero FJ, Luquero FJ, Grout L, Ciglenecki I, Sakoba K, Traore B, Heile M, Diallo AA, Itama C, Page AL, Quilici ML, Mengel MA, Eiros JM, Serafini M, Legros D, Grais RF, , 2014. Use of Vibrio cholerae vaccine in an outbreak in Guinea. N Engl J Med 370: 21112120.[Crossref]
  23. Bhattacharya SK, Sur D, Ali M, Kanungo S, You YA, Manna B, Sah B, Niyogi SK, Park JK, Sarkar B, Puri MK, Kim DR, Deen JL, Holmgren J, Carbis R, Dhingra MS, Donner A, Nair GB, Lopez AL, Wierzba TF, Clemens JD, , 2013. 5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 13: 10501056.[Crossref]
  24. Sur D, Kanungo S, Sah B, Manna B, Ali M, Paisley AM, Niyogi SK, Park JK, Sarkar B, Puri MK, Kim DR, Deen JL, Holmgren J, Carbis R, Rao R, Nguyen TV, Han SH, Attridge S, Donner A, Ganguly NK, Bhattacharya SK, Nair GB, Clemens JD, Lopez AL, , 2011. Efficacy of a low-cost, inactivated whole-cell oral cholera vaccine: results from 3 years of follow-up of a randomized, controlled trial. PLoS Negl Trop Dis 5: e1289.[Crossref]
  25. Barzilay EJ, Schaad N, Magloire R, Mung KS, Boncy J, Dahourou GA, Mintz ED, Steenland MW, Vertefeuille JF, Tappero JW, , 2013. Cholera surveillance during the Haiti epidemic—the first 2 years. N Engl J Med 368: 599609.[Crossref]
  26. Ivers LC, Hilaire IJ, Teng JE, Almazor CP, Jerome JG, Ternier R, Boncy J, Buteau J, Murray MB, Harris JB, Franke MF, , 2015. Effectiveness of reactive oral cholera vaccination in rural Haiti: a case-control study and bias-indicator analysis. Lancet Glob Health 3: e162e168.[Crossref]
  27. Hinman AR, Farmer PE, , 2013. The coalition for cholera prevention and control meeting. Vaccine 31: 2323.[Crossref]
  28. Pape JW, Rouzier V, , 2014. Embracing oral cholera vaccine–shifting response to cholera. N Engl J Med 370: 20672069.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.15-0700
Loading
/content/journals/10.4269/ajtmh.15-0700
Loading

Data & Media loading...

  • Received : 24 Sep 2015
  • Accepted : 11 Dec 2015

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error